269 related articles for article (PubMed ID: 24418061)
1. Biological heterogeneity in ADNI amnestic mild cognitive impairment.
Nettiksimmons J; DeCarli C; Landau S; Beckett L;
Alzheimers Dement; 2014 Sep; 10(5):511-521.e1. PubMed ID: 24418061
[TBL] [Abstract][Full Text] [Related]
2. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
4. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.
Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322
[TBL] [Abstract][Full Text] [Related]
5. Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI.
Ezzati A; Zammit AR; Habeck C; Hall CB; Lipton RB;
Brain Imaging Behav; 2020 Oct; 14(5):1792-1804. PubMed ID: 31104279
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
[TBL] [Abstract][Full Text] [Related]
8. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
9. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.
Leow AD; Yanovsky I; Parikshak N; Hua X; Lee S; Toga AW; Jack CR; Bernstein MA; Britson PJ; Gunter JL; Ward CP; Borowski B; Shaw LM; Trojanowski JQ; Fleisher AS; Harvey D; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM;
Neuroimage; 2009 Apr; 45(3):645-55. PubMed ID: 19280686
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates.
Bondi MW; Edmonds EC; Jak AJ; Clark LR; Delano-Wood L; McDonald CR; Nation DA; Libon DJ; Au R; Galasko D; Salmon DP
J Alzheimers Dis; 2014; 42(1):275-89. PubMed ID: 24844687
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
Drake JD; Chambers AB; Ott BR; Daiello LA;
J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
15. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.
Edmonds EC; Delano-Wood L; Clark LR; Jak AJ; Nation DA; McDonald CR; Libon DJ; Au R; Galasko D; Salmon DP; Bondi MW;
Alzheimers Dement; 2015 Apr; 11(4):415-24. PubMed ID: 24857234
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
18. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
[TBL] [Abstract][Full Text] [Related]
20. CSF Apo-E levels associate with cognitive decline and MRI changes.
Toledo JB; Da X; Weiner MW; Wolk DA; Xie SX; Arnold SE; Davatzikos C; Shaw LM; Trojanowski JQ;
Acta Neuropathol; 2014 May; 127(5):621-32. PubMed ID: 24385135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
